Can T-Cell Engagers Crack Solid Tumors? The Next Frontier in Cancer Immunotherapy
Can we teach the immune system to attack solid tumors more effectively - and potentially create longer-lasting responses for cancer patients? In this episode of Rx for Biotech, host Chris Leidli sits down with Jack Silberstein, Founder and CEO of Deck Bio, to explore the next generation of cancer immunotherapy and why T-cell engagers could become an important new weapon against solid tumors. Jack's path into biotechnology started on the front lines of cancer care. As a clinical research coordinator at Johns Hopkins, he worked directly with patients with metastatic prostate cancer and saw…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.